Tiu Crescens, Pezaro Carmel, Davis Ian D, Grossmann Mathis, Parente Phillip
Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia.
Asia Pac J Clin Oncol. 2015 Jun;11(2):190-4. doi: 10.1111/ajco.12348. Epub 2015 Apr 9.
Ipilimumab is a human anti-CTLA-4 monoclonal antibody recently approved for the treatment of advanced melanoma. Stimulation of T-cell activity unmasks antitumor activity, but can cause immune-related adverse events. Autoimmune hypophysitis is of particular importance because its presentation can be subtle but life threatening. We present two cases where early recognition of ipilimumab-related autoimmune hypophysitis led to timely intervention and low subsequent morbidity, without compromise of antitumor effects. We provide recommendations for detection and management of this potentially life-threatening complication of ipilimumab.
伊匹单抗是一种人抗细胞毒性T淋巴细胞相关抗原4（CTLA-4）单克隆抗体，最近被批准用于治疗晚期黑色素瘤。T细胞活性的刺激可揭示抗肿瘤活性，但可能导致免疫相关不良事件。自身免疫性垂体炎尤为重要，因为其表现可能不明显但危及生命。我们报告两例病例，其中对伊匹单抗相关自身免疫性垂体炎的早期识别导致了及时干预，且随后的发病率较低，同时不影响抗肿瘤效果。我们提供了关于检测和管理伊匹单抗这种潜在危及生命并发症的建议。
